Last reviewed · How we verify
NCT03555292
11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
Phase 2 trial testing 11C-PiB in Parkinson Disease in 200 participants. Status unknown.
12 May 2021
Quick facts
| Lead sponsor | Oriental Neurosurgery Evidence-Based-Study Team |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 12 July 2017 |
| Primary completion | 12 May 2021 |
| Estimated completion | 12 October 2021 |
| Sites | 3 locations across China |
Drugs / interventions tested
- 11C-PiB — full drug profile →
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Oriental Neurosurgery Evidence-Based-Study Team — full company profile →
Who can join
18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel Tracers and Radionuclides in PET Imaging.
Mason C, Gimblet GR, Lapi SE, Lewis JS. · · 2021 · cited 10× · PMID 34392925 · DOI 10.1016/j.rcl.2021.05.012
Verify or expand the search:
- PubMed search for NCT03555292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 11C-PiB
Trials testing the same drug.
- NCT04505735 — Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment · terminated
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Oriental Neurosurgery Evidence-Based-Study Team trials
Trials by the same sponsor.
- NCT06936514 — Clinical Study on Deep Cervical Lymphatic Trunk Decompression Combined With Mid-Cervical Deep Lymph Node-External Jugula · NA · enrolling by invitation
- NCT05396209 — To Evaluate the Therapeutic Efficacy of Hydrated Amniotic Membrane in Promoting Closure of Refractory Macular Holes. · NA · unknown
- NCT03620552 — 18F-S16 PET/CT in Healthy Volunteers and Patients With Neurodegenerative Dementia · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03555292 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oriental Neurosurgery Evidence-Based-Study Team
- Last refreshed: 13 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03555292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing